ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.331,39
-0,25%
S&P 500
5.469,30
0,39%
US Dollar vs BRL
5,4522
0,00%
Bitcoin
62.054,06
0,41%
Brent Oil
84,32
0,16%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Spyre Therapeutics Inc (SYRE)

  7. Spyre Therapeutics Inc (SYRE) Notícias

SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SYRE
DataHoraFonteTítuloCódigoCompanhia
18/06/202408:30PR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseNASDAQ:SYRESpyre Therapeutics Inc
03/06/202418:23PR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
30/05/202417:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
29/05/202409:30PR Newswire (US)Spyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SYRESpyre Therapeutics Inc
16/05/202417:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
16/05/202417:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
15/05/202408:30PR Newswire (US)Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
09/05/202417:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRESpyre Therapeutics Inc
09/05/202417:02PR Newswire (US)Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
18/03/202409:00PR Newswire (US)Spyre Therapeutics Announces $180 Million Private PlacementNASDAQ:SYRESpyre Therapeutics Inc
05/03/202419:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SYRESpyre Therapeutics Inc
01/03/202408:14Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
29/02/202419:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRESpyre Therapeutics Inc
29/02/202418:05PR Newswire (US)Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
26/02/202409:30PR Newswire (US)Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:SYRESpyre Therapeutics Inc
14/02/202422:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
08/02/202409:30PR Newswire (US)Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis OrganisationNASDAQ:SYRESpyre Therapeutics Inc
05/02/202409:30PR Newswire (US)Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of DirectorsNASDAQ:SYRESpyre Therapeutics Inc
29/12/202319:00Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
26/12/202323:56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SYRESpyre Therapeutics Inc
22/12/202318:32Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SYRESpyre Therapeutics Inc
08/12/202318:07Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
08/12/202318:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SYRESpyre Therapeutics Inc
08/12/202318:03Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
01/12/202318:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRESpyre Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SYRE

Seu Histórico Recente

LSE
AN66
Citi Fun 29
COIN
BIDGBP
Bidao
NASDAQ
ZING
FTAC Zeus Acquisition
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados